Antikor – BioExpert Network

ANTIKOR

Next-generation Antibody Fragment Drug Conjugates

OWNER

(See Profile)

Sector

Cancer therapeutics

Stage

Pre-clinical

Funding needed

£ 1 000 000

Country

Fragment Drug Conjugates greatly improve delivery of drug payload in malignant cells compared to traditional ADC

FDC need lower doses to act, they are better tolerated and have fewer side effects

ADC market (currently $ 2.0b) expected to more than double by 2020

Strong IP to protect products until 2034

Download PDF

If you want to have more information or you want to review the project, you have to login or register

Share your thoughts with other BioExperts

KEEP REVIEWING

Funding: 5.000.000$
Stage: Development, market readiness, clinical trial
Sector: Biotech
+

BioZen Limited

BioZen Limited Developing the world's first approved medica...
Funding: 500.000€
Stage: Development, market readiness, clinical trial
Sector: Medical Device
+

Laboratorios Isimo, SL

Laboratorios Isimo, SL Laboratorios Isimo, SL Medical Devic...

OWNER

Sector

Stage

Funding needed

Country

Fragment Drug Conjugates greatly improve delivery of drug payload in malignant cells compared to traditional ADC

FDC need lower doses to act, they are better tolerated and have fewer side effects

ADC market (currently $ 2.0b) expected to more than double by 2020

Strong IP to protect products until 2034

BioZen Limited

Laboratorios Isimo, SL

Capital Cell Barcelona

Links

About cookies

OWNER

Sector

Stage

Funding needed

Country

Fragment Drug Conjugates greatly improve delivery of drug payload in malignant cells compared to traditional ADC

FDC need lower doses to act, they are better tolerated and have fewer side effects

ADC market (currently $ 2.0b) expected to more than double by 2020

Strong IP to protect products until 2034

BioZen Limited

Laboratorios Isimo, SL

Capital Cell Barcelona

Links

About cookies

Log in with your credentials

Forgot your details?

Create Account